Post by Confo Therapeutics

New data presented at ENDO 2026 demonstrate the potential of CFTX-2034, Confo Therapeutics’ SSTR5 agonistic antibody, as a first-in-class treatment for post-bariatric hypoglycemia (PBH). The preclinical results support the program’s progression towards clinical development and underscore our commitment to advancing innovative therapies for endocrine and metabolic diseases. Read the full press release here: https://lnkd.in/eTEm_zJx